Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, and HIV/AIDS drug development and treatment.
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions
The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia
Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
Joint statement in support of hepatitis C human challenge studies
New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK
An informatics consult approach for generating clinical evidence for treatment decisions
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study
Computational modelling and experimental tank testing of the multi float WaveSub under regular wave forcing
Interferon lambda 4 impacts the genetic diversity of hepatitis C virus
Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK
Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol)
The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus‐infected people who inject drugs in England
Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome
Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK
Chronic hepatitis B virus monoinfection at a university hospital in Zambia
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus
MAIT cells are activated during human viral infections
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials